Bilcare Ltd

Bilcare's capital structure is characterized by a debt-to-equity ratio of 1.45, indicating a moderate reliance on debt financing. The company's liquidity position is weak, with cash and equivalents amounting to only INR 7.83 million, while long-term debt stands at INR 6.82 billion. The current ratio of 1.01 suggests the company is barely able to cover its short-term liabilities with its short-term assets. The price-to-book ratio of 3.82 implies that the market values the company at a premium to its book value, despite its negative net income and operating losses. Profitability metrics for Bilcare are concerning. The company reported a net loss of INR 288 million and an operating loss of INR 209 million in the latest period. Return on equity (ROE) is negative at -6.14%, and return on assets (ROA) is also negative at -2.03%. These figures are below the industry median for profitability, which typically includes positive ROE and ROA for firms in the packaging and pharmaceutical services sector. Gross profit of INR 2.49 billion is insufficient to cover operating expenses, contributing to the company's unprofitable performance. Bilcare operates as a single-segment company, with all revenue derived from its Pharma Packaging Research Solutions segment. The company's geographic exposure is concentrated in India, with manufacturing facilities in Nashik, Pune, and Thane. There is no indication of significant international revenue diversification in the latest financial data. The company's revenue concentration in a single segment and geographic region increases its vulnerability to local economic and regulatory changes. The company's growth trajectory is mixed. Revenue for the latest period was INR 7.88 billion, but the company reported a net loss. Analyst estimates suggest a last actual revenue of INR 35.47 billion, which may reflect a prior period or a different reporting standard. The outlook for the current fiscal year is uncertain, with no clear indication of a turnaround in profitability. The company's free cash flow is negative at INR -329 million, and capital expenditures of INR -226 million indicate ongoing investment in operations, which may not yet be yielding returns. Risk factors for Bilcare include its weak liquidity position and high debt load. The company's net cash is negative after subtracting total debt, and its liquidity risk is rated as medium. The dilution risk is low, but the company's negative operating cash flow and free cash flow suggest potential pressure to raise additional capital in the future. The risk assessment also highlights the company's inability to generate positive cash flows from operations, which could lead to further financial strain. Recent events and disclosures indicate that Bilcare has a single operating segment and five subsidiaries, including Bilcare GCS Limited, Bilcare Inc., and others. The company's annual manufacturing capacity is approximately 50,000 tons, and it has a focus on pharmaceutical packaging solutions such as blister films and foils. The company's R&D services include formulation stability studies and blister/foil design and development. These services are part of its broader strategy to provide end-to-end solutions in the pharmaceutical packaging and clinical services space.